PNC-27 - 5MG

PNC-27

PNC-27 is a synthetic 32–residue peptide that fuses the p53 HDM-2–binding domain (aa 12–26) to a cell-penetrating leader sequence, enabling selective targeting and killing of cancer cells that present HDM-2 on their plasma membranes—sparing normal, untransformed cells.^[1–4]

Mechanism of Action

• Binds the p53-binding site of HDM-2 (aa 1–109) on cancer cell membranes, forming a 1:1 complex that triggers transmembrane pore formation → rapid necrosis via membrane disruption and loss of integrity.^[1,5–7]
• Immuno-EM and colocalization studies show PNC-27 and HDM-2 assemble as ring-like structures lining the pores.^[1,5]

Spectrum of Activity

• Cytotoxic to diverse solid and hematologic malignancies (breast, pancreatic, colon, cervical, ovarian; AML; p53-null leukemia) and to cancer stem-like cells expressing membrane HDM-2; induces tumor-nodule necrosis in vivo.^[2–4,8,9]

Selectivity & Safety

• Normal cells (e.g., fibroblasts, lymphocytes, untransformed epithelia) lack membrane HDM-2 and resist lysis; forced membrane-localization of HDM-2 confers susceptibility—confirming target specificity.^[1–3,7]

Additional Mechanisms

• Also disrupts mitochondrial membranes in cancer cells, augmenting cell death; activity requires the intact peptide (both N- and C-termini).^[6,7]

Synergy with Chemotherapy

• Shows synergy with paclitaxel in ovarian cancer models, targeting chemotherapy-surviving cells with increased membrane HDM-2.^[9]

Summary

By selectively engaging membrane-bound HDM-2 to form cytolytic pores—while sparing normal cells—PNC-27 presents a distinctive, target-directed approach for oncology research, with supportive data across multiple tumor types and combinational strategies.^[1–9]

References

1. Sarafraz-Yazdi E, Bowne WB, Adler V, et al. PNAS. 2010;107(5):1918-23.
2. Krzesaj PK, Seydafkan S, Miller AI, et al. Ann Clin Lab Sci. 2025;55(3):347-353.
3. Davitt K, Babcock BD, Fenelus M, et al. Cancer Chemother Pharmacol. 2010;66(2):325-331.
4. Thadi A, Morano WF, Khalili M, et al. Anticancer Res. 2021;41(1):27-42.
5. Sarafraz-Yazdi E, Mumin S, Cheung D, et al. Biomedicines. 2022;10(5):945.
6. Krzesaj P, Adler V, Feinman RD, et al. Ann Clin Lab Sci. 2024;54(2):137-148.
7. Sookraj KA, Bowne WB, Adler V, et al. Cancer Chemother Pharmacol. 2010;66(2):325-331.
8. Thadi A, Lewis L, Goldstein E, et al. Anticancer Res. 2020;40(9):4857-4867.
9. Alagkiozidis I, Gorelick C, Shah T, et al. Ann Clin Lab Sci. 2017;47(3):271-281.

All COA’s avail upon request by email info@truformlabs.com.

Storage & Handling (Research Use)

• Lyophilized (dry) peptide: Store sealed at −20 °C for long-term stability. Short-term (≤2–3 weeks) at 2–8 °C is acceptable.
• After reconstitution: Store at 2–8 °C and use within 7 days, or aliquot into sterile vials and freeze at −20 °C for up to 3 months.
• Light & moisture: Protect from light; keep container tightly closed to avoid moisture uptake.
• Freeze–thaw: Avoid repeated freeze–thaw cycles; prepare small aliquots.
• Solvent compatibility: Use a sterile, compatible solvent per protocol; filter-sterilize if required.
• Labeling: Clearly label aliquots with concentration, solvent, and preparation date.

Storage guidance is general for research peptides and may be adapted to your lab SOP.